<?xml version="1.0" encoding="UTF-8"?>
<ref id="B44-vaccines-07-00053">
 <label>44.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Giles</surname>
    <given-names>B.M.</given-names>
   </name>
   <name>
    <surname>Bissel</surname>
    <given-names>S.J.</given-names>
   </name>
   <name>
    <surname>Dealmeida</surname>
    <given-names>D.R.</given-names>
   </name>
   <name>
    <surname>Wiley</surname>
    <given-names>C.A.</given-names>
   </name>
   <name>
    <surname>Ross</surname>
    <given-names>T.M.</given-names>
   </name>
  </person-group>
  <article-title>Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines</article-title>
  <source>Clin. Vaccine Immunol.</source>
  <year>2012</year>
  <volume>19</volume>
  <fpage>128</fpage>
  <lpage>139</lpage>
  <pub-id pub-id-type="doi">10.1128/CVI.05533-11</pub-id>
  <?supplied-pmid 22190399?>
  <pub-id pub-id-type="pmid">22190399</pub-id>
 </element-citation>
</ref>
